Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Date:1/25/2008

SAN DIEGO, Jan. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Merck & Co., Inc. initiated a Phase 1 clinical trial of a second generation oral niacin receptor agonist under a collaboration between the companies to discover drugs for the treatment of atherosclerosis and other disorders. The initiation of this trial does not trigger a milestone payment.

"We are very pleased with the progress of this collaboration investigating the therapeutic potential of niacin receptor agonists to treat atherosclerosis and other disorders. We are looking forward to the Phase 1 results and the continued progress of the program," said Jack Lief, Arena's President and Chief Executive Officer.

Arena also announced that preclinical investigation of MK-0354, a first generation niacin receptor agonist being evaluated for indications other than atherosclerosis, was discontinued for compound specific reasons.

About Atherosclerosis

Atherosclerosis is characterized by the collection of fatty material deposits, such as cholesterol, along artery walls. This fatty material thickens, hardens, and may eventually block the arteries, adversely affecting blood flow and increasing the risk of heart attack and stroke over time. The American Heart Association estimates that atherosclerosis accounts for nearly 75% of all deaths from cardiovascular disease. HDL cholesterol, commonly known as the "good" cholesterol, can help clear the fatty deposits from the walls of blood vessels and transport cholesterol to the liver for processing and removal from the body. Drugs that can influence the levels of HDL cholesterol, or "good" cholesterol, may potentially provide clinical benefits to patients by reducing the
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
2. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
3. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
4. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
9. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 PMG Research, Inc. ... Research is a network of sites that provide clinical research ... 2 million patient lives through its partnerships with large physician ... 11 hub site locations in the Southeastern United States and ... of the board will be held by: Dr. ...
(Date:11/26/2014)... PA (PRWEB) November 25, 2014 The ... of its official conference and exposition mobile app, ... for free download in the App Store for iOS ... a valuable resource tool before, during and after the ... containing details on exhibiting companies, technical sessions, Conferee Networking ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is an in-depth research report on the Global ... report introduces Palmitic Acid, basic information, including definition, ... analysis, and news analysis, etc. , For ... Palmitic Acid market in China and ...
(Date:11/24/2014)... N.J. , Nov. 24, 2014  IGI Laboratories, ... based specialty generic pharmaceutical company, today announced ... (ANDA) to the U.S. Food and Drug Administration (FDA), ... in 2014 to seven, with eighteen submissions now pending ... , President and CEO of the Company, commented, "Our ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Pittcon Releases 2015 Mobile App 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3IGI Laboratories, Inc. Announces ANDA Submission 2
... SHANGHAI, China Genzyme,Corp. (Nasdaq: GENZ ) ... they,will collaborate to manufacture, develop, and commercialize the,experimental ... Genzyme,s,most advanced gene therapy candidate and is currently ... and Europe. Sunway is a privately-held, Shanghai-based ...
... Inc. (Nasdaq: CEGE ), today announced that Stephen ... E. Tetlow, senior,vice president and chief financial officer of ... company,s third quarter financial results,that will be broadcast live ... p.m. PT/ 5:00 p.m. ET. The webcast will ...
... Kosan Biosciences,Inc. (Nasdaq: KOSN ) today announced ... on Wednesday, October 31, 2007, beginning at approximately,7:30 ... addition to,presentations by Kosan,s Executives, Robert G. Johnson, ... Pieter Timmermans, Ph.D., Senior,Vice President, Drug Discovery and ...
Cached Biology Technology:Genzyme and Sunway to Collaborate on Gene Therapy Program in China 2Genzyme and Sunway to Collaborate on Gene Therapy Program in China 3Genzyme and Sunway to Collaborate on Gene Therapy Program in China 4Cell Genesys to Webcast Third Quarter 2007 Conference Call 2Kosan Biosciences to Host Research & Development Day on October 31, 2007 2Kosan Biosciences to Host Research & Development Day on October 31, 2007 3
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... N.C. In a finding that confirms what many ... younger women who undergo hysterectomies face a nearly two-fold ... published in the December issue of the journal ... track over time the actual hormonal impact of woman ...
... November 14, 2011 The possibility that functional, ... cells, such as embryonic stem cells (ESCs) and induced ... challenges of stem cell research, but is also one ... regenerative medicine. Developmental biology has played a central role ...
... CLEVELAND -- An estimated 300,000 people in North ... a progressive loss of motor control. Patients with generalized ... uncontrolled twisting and turning in awkward, sometimes painful postures. ... the disorder can have a devastating impact on quality ...
Cached Biology News:Hysterectomy increases risk for earlier menopause among younger women 2Self-organized pituitary-like tissue from mouse ES cells 2Self-organized pituitary-like tissue from mouse ES cells 3Self-organized pituitary-like tissue from mouse ES cells 4University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 2University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 3
...
Luminometers...
... Designed for serial preparation ... fractions including cytosol/particulate/cytoskeleton/nuclear fractions ... these fractions can directly ... assays such as 2-D ...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
Biology Products: